| Status: | Phase 2 |
| Entry Type: | Small molecule |
| Molecule Category: | UNKNOWN |
| UNII: | 51M3FB9B9E |
Physicochemical Descriptors
| Property Name | Value |
|---|---|
| Molecular Formula | C25H36F3N5O3 |
| Molecular Weight | 511.59 |
| AlogP | 2.87 |
| Hydrogen Bond Acceptor | 7.0 |
| Hydrogen Bond Donor | 1.0 |
| Number of Rotational Bond | 6.0 |
| Polar Surface Area | 79.82 |
| Molecular species | None |
| Aromatic Rings | 1.0 |
| Heavy Atoms | 36.0 |
Pharmacology
| Action | Mechanism of Action | Reference |
|---|---|---|
| ANTAGONIST | C-C chemokine receptor type 2 antagonist |
Indications
| Mesh Heading | Maximum Phase | Mesh ID | Reference |
|---|---|---|---|
| Diabetic Nephropathies | 2 | D003928 | ClinicalTrials |
| Renal Insufficiency | 1 | D051437 | ClinicalTrials |
Cross References
| Resources | Reference |
|---|---|
| CAS NUMBER | 1228111-63-4 |
| ChEMBL | CHEMBL3545032 |
| FDA SRS | 51M3FB9B9E |
| Guide to Pharmacology | 9979 |
| PubChem | 46198579 |
CONTENTS